Oncology billing is not like billing for a primary care visit or even a surgical procedure. A massive piece of oncology revenue comes from drugs administered in the office. And those drugs bring a billing and compliance burden that most other specialties never have to deal with.
Between buy-and-bill pricing, Average Sales Price (ASP) updates, National Drug Code requirements, and payer-specific drug policies, the room for error is wide and the financial consequences are steep. Let us break down the areas where oncology practices lose the most money and face the most regulatory exposure.
The Buy-&-Bill Model & Why It Matters
Most oncology drugs administered in the office follow a buy-and-bill model. The practice purchases the drug from a wholesaler or specialty distributor, administers it to the patient, and then bills the payer for reimbursement. The practice earns revenue on the margin between the acquisition cost and the payer’s reimbursement rate.
For Medicare, that reimbursement rate is ASP plus 6%. The ASP is updated quarterly by CMS, and it is based on manufacturer-reported sales data. When ASP drops between quarters, a drug the practice purchased at a higher price may now be reimbursed at a lower rate. That margin squeeze is real, and it hits hardest on high-cost oncology drugs where the per-dose acquisition cost can run into thousands of dollars.
Practices that do not track ASP updates quarterly and adjust their purchasing and inventory management accordingly end up losing money on drugs they have already bought and administered. This is not a theoretical problem. It happens every quarter.
HCPCS Coding for Drugs: Getting the Units Right
Every injectable and infusible drug billed to a payer requires a HCPCS J-code. The J-code defines the drug and the unit of measurement. Here is where it gets tricky: the billing unit in the HCPCS code does not always match the dose prescribed by the oncologist.
For example, if a J-code is defined as 1 mg and the patient receives 150 mg, the practice bills 150 units. If the J-code is defined per 10 mg and the patient gets 150 mg, the practice bills 15 units. Get the unit conversion wrong, and you either underbill (leaving money on the table) or overbill (creating a compliance issue that invites audit attention).
Wastage reporting adds another layer. When a single-use vial contains more drug than the patient receives, the unused portion is billed using modifier JW. Medicare requires reporting of discarded drug amounts, and failure to do so can trigger audits and recovery demands. On the other hand, practices that do not bill for wastage are effectively absorbing the cost of unused drug that they could legally recover.
Prior Authorization & Step Therapy Delays
Oncology drugs are among the most heavily managed by payers when it comes to prior authorization. Before a patient can receive treatment, the practice often has to submit clinical documentation proving medical necessity, show that the prescribed drug is the appropriate option based on the payer’s formulary and step therapy requirements, and wait for approval.
Delays in prior authorization directly affect patient care and practice revenue. If a drug is administered before authorization is confirmed, the claim will be denied. If the authorization expires before the next cycle of treatment, the practice has to start the process over. Some payers require re-authorization for each cycle or after a defined number of treatments.
Practices that do not have a dedicated prior authorization workflow for oncology drugs lose revenue to denied claims and face delays that disrupt treatment schedules. A structured system that tracks authorization status, expiration dates, and re-authorization timelines is not optional in oncology.
National Drug Code (NDC) Reporting
Many payers now require NDC numbers on drug claims in addition to the HCPCS J-code. The NDC identifies the specific manufacturer, package size, and product formulation. If the NDC does not match the J-code, or if it is missing entirely, the claim can be denied for manual review.
This creates a documentation burden at the point of administration. The person preparing the drug needs to capture the NDC from the vial or package, and that information must flow accurately into the billing system. Practices that rely on manual entry for NDC data are more prone to errors than those that use barcode scanning or automated charge capture systems.
Compliance Risks Around Drug Reimbursement
Oncology drug billing is a high-priority target for federal enforcement. The Office of Inspector General regularly includes oncology drug reimbursement in its annual work plan. Areas of focus include billing for drugs not administered, billing for brand-name drugs when generics or biosimilars were used, inaccurate wastage reporting, and improper use of drug samples.
Practices that do not reconcile their drug inventory against claims data are at risk. If the number of doses billed exceeds the number of doses purchased, that discrepancy will be found during an audit. Regular internal audits comparing drug inventory, purchase records, and claims submissions are the most effective way to catch errors before an external auditor does.
Infusion Coding & Time-Based Billing
Beyond the drug itself, oncology billing includes the administration service. Chemotherapy administration codes are time-based and follow specific rules about initial versus sequential infusions, push injections, and concurrent administrations. The first hour of infusion is billed differently from each additional hour, and the coding changes depending on the method of delivery.
If a patient receives two drugs through sequential infusion, the coding must reflect the order and timing of each drug. Billing staff need access to accurate infusion start and stop times from the nursing documentation. When those times are vague or missing, the billing team has to guess, and guessing in oncology billing leads to either underbilling or audit risk.
Keeping Up
Oncology billing sits at the intersection of drug pricing, clinical compliance, and payer regulation. The practices that stay profitable and compliant are the ones that invest in trained billing staff, maintain tight inventory controls, track ASP changes quarterly, and audit their drug claims regularly. The financial stakes in oncology are too high to treat billing as an afterthought. Every dose, every unit, and every modifier has to be right.